Osimertinib is approved for the treatment of non-small-cell lung cancer in patients who develop the EGFR Thr790Met mutation after treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs). We assessed outcomes in patients with non-small-cell lung cancer and the EGFR Thr790Met mutation who were treated with osimertinib, a third-generation EGFR TKI, after previous treatment failure with one or more other EGFR TKIs.

中文翻译：

---

基因组研究：使用奥美替尼治疗非小细胞肺癌并获得Thr790Met突变的患者的结果。

奥西替尼被批准用于治疗表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）后出现EGFR Thr790Met突变的患者的非小细胞肺癌。我们评估了非小细胞肺癌和EGFR Thr790Met突变的患者的结局，这些患者先前用一种或多种其他EGFR TKI治疗失败后接受了第三代EGFR TKI奥西替尼治疗。